Pharmacologic and Nonpharmacologic Treatment of Restless Legs Syndrome

Galia V Anguelova; Monique H M Vlak; Arthur G Y Kurvers; Roselyne M Rijsman

doi:10.1016/j.jsmc.2020.02.013

Pharmacologic and Nonpharmacologic Treatment of Restless Legs Syndrome

Sleep Med Clin. 2020 Jun;15(2):277-288. doi: 10.1016/j.jsmc.2020.02.013.

Authors

Galia V Anguelova¹, Monique H M Vlak¹, Arthur G Y Kurvers¹, Roselyne M Rijsman²

Affiliations

¹ Center for Sleep and Wake Disorders, Haaglanden Medical Center, The Hague, The Netherlands.
² Center for Sleep and Wake Disorders, Haaglanden Medical Center, The Hague, The Netherlands. Electronic address: r.rijsman@haaglandenmc.nl.

PMID: 32386701
DOI: 10.1016/j.jsmc.2020.02.013

Abstract

This article provides an updated practical guide for the treatment of primary restless legs syndrome (RLS). Articles that appeared after the American Academy of Neurology guideline search were reviewed according to the same evidence rating schedule. We found limited evidence for nonpharmacologic treatment options. In moderate to severe primary RLS, pharmacologic options may be considered, including iron suppletion, an α2δ ligand, a dopamine agonist, a combination of an α2δ ligand and a dopamine agonist, or oxycodone/naloxone. This article includes treatment options in case of augmentation.

Keywords: Augmentation; Nonpharmacologic; Pharmacologic; Restless legs syndrome; Therapy; Treatment.

Publication types

Review

MeSH terms

Dopamine Agonists / therapeutic use*
Humans
Restless Legs Syndrome / drug therapy
Restless Legs Syndrome / therapy*

Substances

Dopamine Agonists